nodes	percent_of_prediction	percent_of_DWPC	metapath
Methazolamide—CYP2C19—Ifosfamide—testicular cancer	0.105	0.187	CbGbCtD
Methazolamide—CYP2C9—Ifosfamide—testicular cancer	0.087	0.155	CbGbCtD
Methazolamide—CYP2E1—Etoposide—testicular cancer	0.0798	0.143	CbGbCtD
Methazolamide—SLC22A6—Methotrexate—testicular cancer	0.0599	0.107	CbGbCtD
Methazolamide—CYP3A4—Ifosfamide—testicular cancer	0.0506	0.0904	CbGbCtD
Methazolamide—CYP2C9—Cisplatin—testicular cancer	0.0423	0.0756	CbGbCtD
Methazolamide—CYP2D6—Vinblastine—testicular cancer	0.0422	0.0754	CbGbCtD
Methazolamide—CYP3A4—Vinblastine—testicular cancer	0.0268	0.0479	CbGbCtD
Methazolamide—CYP2D6—Doxorubicin—testicular cancer	0.0259	0.0463	CbGbCtD
Methazolamide—CYP3A4—Etoposide—testicular cancer	0.0242	0.0432	CbGbCtD
Methazolamide—CYP3A4—Doxorubicin—testicular cancer	0.0165	0.0295	CbGbCtD
Methazolamide—Erythema multiforme—Dactinomycin—testicular cancer	0.00198	0.00449	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Etoposide—testicular cancer	0.00197	0.00448	CcSEcCtD
Methazolamide—Anorexia—Chlorambucil—testicular cancer	0.00196	0.00446	CcSEcCtD
Methazolamide—Pancytopenia—Cisplatin—testicular cancer	0.00196	0.00445	CcSEcCtD
Methazolamide—Discomfort—Vinblastine—testicular cancer	0.00194	0.00442	CcSEcCtD
Methazolamide—Glycosuria—Doxorubicin—testicular cancer	0.00193	0.00439	CcSEcCtD
Methazolamide—Blood disorder—Doxorubicin—testicular cancer	0.00187	0.00425	CcSEcCtD
Methazolamide—Erythema multiforme—Ifosfamide—testicular cancer	0.00181	0.00412	CcSEcCtD
Methazolamide—Dyspepsia—Chlorambucil—testicular cancer	0.00181	0.00412	CcSEcCtD
Methazolamide—Ill-defined disorder—Bleomycin—testicular cancer	0.00181	0.00412	CcSEcCtD
Methazolamide—Anorexia—Vinblastine—testicular cancer	0.0018	0.00409	CcSEcCtD
Methazolamide—Pancytopenia—Etoposide—testicular cancer	0.0018	0.00408	CcSEcCtD
Methazolamide—Decreased appetite—Chlorambucil—testicular cancer	0.00179	0.00407	CcSEcCtD
Methazolamide—Tinnitus—Ifosfamide—testicular cancer	0.00179	0.00406	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.00178	0.00404	CcSEcCtD
Methazolamide—Fatigue—Chlorambucil—testicular cancer	0.00177	0.00403	CcSEcCtD
Methazolamide—Melaena—Methotrexate—testicular cancer	0.00176	0.00401	CcSEcCtD
Methazolamide—Malaise—Bleomycin—testicular cancer	0.00176	0.004	CcSEcCtD
Methazolamide—Leukopenia—Bleomycin—testicular cancer	0.00175	0.00397	CcSEcCtD
Methazolamide—Feeling abnormal—Chlorambucil—testicular cancer	0.0017	0.00385	CcSEcCtD
Methazolamide—Aplastic anaemia—Methotrexate—testicular cancer	0.00169	0.00385	CcSEcCtD
Methazolamide—Paraesthesia—Vinblastine—testicular cancer	0.00169	0.00385	CcSEcCtD
Methazolamide—Ill-defined disorder—Dactinomycin—testicular cancer	0.00169	0.00384	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Etoposide—testicular cancer	0.00167	0.0038	CcSEcCtD
Methazolamide—Melaena—Epirubicin—testicular cancer	0.00165	0.00375	CcSEcCtD
Methazolamide—Discomfort—Bleomycin—testicular cancer	0.00164	0.00373	CcSEcCtD
Methazolamide—Malaise—Dactinomycin—testicular cancer	0.00164	0.00373	CcSEcCtD
Methazolamide—Decreased appetite—Vinblastine—testicular cancer	0.00164	0.00373	CcSEcCtD
Methazolamide—Urticaria—Chlorambucil—testicular cancer	0.00163	0.00372	CcSEcCtD
Methazolamide—Urine output increased—Methotrexate—testicular cancer	0.00163	0.00371	CcSEcCtD
Methazolamide—Leukopenia—Dactinomycin—testicular cancer	0.00163	0.0037	CcSEcCtD
Methazolamide—Body temperature increased—Chlorambucil—testicular cancer	0.00163	0.0037	CcSEcCtD
Methazolamide—Confusional state—Bleomycin—testicular cancer	0.00161	0.00365	CcSEcCtD
Methazolamide—Anaphylactic shock—Bleomycin—testicular cancer	0.00159	0.00362	CcSEcCtD
Methazolamide—Aplastic anaemia—Epirubicin—testicular cancer	0.00159	0.00361	CcSEcCtD
Methazolamide—Agranulocytosis—Etoposide—testicular cancer	0.00157	0.00358	CcSEcCtD
Methazolamide—Feeling abnormal—Vinblastine—testicular cancer	0.00155	0.00353	CcSEcCtD
Methazolamide—Ill-defined disorder—Ifosfamide—testicular cancer	0.00155	0.00352	CcSEcCtD
Methazolamide—Tinnitus—Cisplatin—testicular cancer	0.00154	0.0035	CcSEcCtD
Methazolamide—Discomfort—Dactinomycin—testicular cancer	0.00153	0.00348	CcSEcCtD
Methazolamide—Melaena—Doxorubicin—testicular cancer	0.00153	0.00347	CcSEcCtD
Methazolamide—Anorexia—Bleomycin—testicular cancer	0.00152	0.00345	CcSEcCtD
Methazolamide—Malaise—Ifosfamide—testicular cancer	0.0015	0.00342	CcSEcCtD
Methazolamide—Vertigo—Ifosfamide—testicular cancer	0.0015	0.00341	CcSEcCtD
Methazolamide—Leukopenia—Ifosfamide—testicular cancer	0.00149	0.00339	CcSEcCtD
Methazolamide—Photosensitivity—Methotrexate—testicular cancer	0.00149	0.00339	CcSEcCtD
Methazolamide—Polyuria—Methotrexate—testicular cancer	0.00149	0.00339	CcSEcCtD
Methazolamide—Asthenia—Chlorambucil—testicular cancer	0.00148	0.00336	CcSEcCtD
Methazolamide—Aplastic anaemia—Doxorubicin—testicular cancer	0.00147	0.00334	CcSEcCtD
Methazolamide—Hepatic failure—Methotrexate—testicular cancer	0.00146	0.00331	CcSEcCtD
Methazolamide—Convulsion—Ifosfamide—testicular cancer	0.00145	0.00328	CcSEcCtD
Methazolamide—Erythema multiforme—Etoposide—testicular cancer	0.00143	0.00325	CcSEcCtD
Methazolamide—Paraesthesia—Bleomycin—testicular cancer	0.00143	0.00325	CcSEcCtD
Methazolamide—Anorexia—Dactinomycin—testicular cancer	0.00142	0.00322	CcSEcCtD
Methazolamide—Diarrhoea—Chlorambucil—testicular cancer	0.00141	0.0032	CcSEcCtD
Methazolamide—Discomfort—Ifosfamide—testicular cancer	0.0014	0.00319	CcSEcCtD
Methazolamide—Photosensitivity—Epirubicin—testicular cancer	0.0014	0.00317	CcSEcCtD
Methazolamide—Decreased appetite—Bleomycin—testicular cancer	0.00138	0.00315	CcSEcCtD
Methazolamide—Confusional state—Ifosfamide—testicular cancer	0.00137	0.00312	CcSEcCtD
Methazolamide—Hepatic failure—Epirubicin—testicular cancer	0.00136	0.0031	CcSEcCtD
Methazolamide—Anaphylactic shock—Ifosfamide—testicular cancer	0.00136	0.00309	CcSEcCtD
Methazolamide—Asthenia—Vinblastine—testicular cancer	0.00135	0.00308	CcSEcCtD
Methazolamide—Ill-defined disorder—Cisplatin—testicular cancer	0.00133	0.00303	CcSEcCtD
Methazolamide—Feeling abnormal—Bleomycin—testicular cancer	0.00131	0.00298	CcSEcCtD
Methazolamide—Vomiting—Chlorambucil—testicular cancer	0.00131	0.00297	CcSEcCtD
Methazolamide—Anorexia—Ifosfamide—testicular cancer	0.0013	0.00295	CcSEcCtD
Methazolamide—Malaise—Cisplatin—testicular cancer	0.0013	0.00295	CcSEcCtD
Methazolamide—Photosensitivity—Doxorubicin—testicular cancer	0.00129	0.00294	CcSEcCtD
Methazolamide—Decreased appetite—Dactinomycin—testicular cancer	0.00129	0.00294	CcSEcCtD
Methazolamide—Diarrhoea—Vinblastine—testicular cancer	0.00129	0.00293	CcSEcCtD
Methazolamide—Dysgeusia—Etoposide—testicular cancer	0.00129	0.00293	CcSEcCtD
Methazolamide—Leukopenia—Cisplatin—testicular cancer	0.00129	0.00293	CcSEcCtD
Methazolamide—Fatigue—Dactinomycin—testicular cancer	0.00128	0.00291	CcSEcCtD
Methazolamide—Urticaria—Bleomycin—testicular cancer	0.00127	0.00288	CcSEcCtD
Methazolamide—Hepatic failure—Doxorubicin—testicular cancer	0.00126	0.00287	CcSEcCtD
Methazolamide—Body temperature increased—Bleomycin—testicular cancer	0.00126	0.00286	CcSEcCtD
Methazolamide—Convulsion—Cisplatin—testicular cancer	0.00125	0.00283	CcSEcCtD
Methazolamide—Feeling abnormal—Dactinomycin—testicular cancer	0.00122	0.00278	CcSEcCtD
Methazolamide—Nausea—Chlorambucil—testicular cancer	0.00122	0.00278	CcSEcCtD
Methazolamide—Paraesthesia—Ifosfamide—testicular cancer	0.00122	0.00278	CcSEcCtD
Methazolamide—Ill-defined disorder—Etoposide—testicular cancer	0.00122	0.00278	CcSEcCtD
Methazolamide—Somnolence—Ifosfamide—testicular cancer	0.00121	0.00275	CcSEcCtD
Methazolamide—Discomfort—Cisplatin—testicular cancer	0.00121	0.00275	CcSEcCtD
Methazolamide—Vomiting—Vinblastine—testicular cancer	0.0012	0.00273	CcSEcCtD
Methazolamide—Malaise—Etoposide—testicular cancer	0.00119	0.0027	CcSEcCtD
Methazolamide—Vertigo—Etoposide—testicular cancer	0.00118	0.00269	CcSEcCtD
Methazolamide—Decreased appetite—Ifosfamide—testicular cancer	0.00118	0.00269	CcSEcCtD
Methazolamide—Headache—Vinblastine—testicular cancer	0.00118	0.00269	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Methotrexate—testicular cancer	0.00118	0.00268	CcSEcCtD
Methazolamide—Leukopenia—Etoposide—testicular cancer	0.00118	0.00268	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00118	0.00267	CcSEcCtD
Methazolamide—Body temperature increased—Dactinomycin—testicular cancer	0.00117	0.00267	CcSEcCtD
Methazolamide—Fatigue—Ifosfamide—testicular cancer	0.00117	0.00267	CcSEcCtD
Methazolamide—Anaphylactic shock—Cisplatin—testicular cancer	0.00117	0.00267	CcSEcCtD
Methazolamide—Asthenia—Bleomycin—testicular cancer	0.00114	0.0026	CcSEcCtD
Methazolamide—Convulsion—Etoposide—testicular cancer	0.00114	0.00259	CcSEcCtD
Methazolamide—Feeling abnormal—Ifosfamide—testicular cancer	0.00112	0.00255	CcSEcCtD
Methazolamide—Nausea—Vinblastine—testicular cancer	0.00112	0.00255	CcSEcCtD
Methazolamide—Anorexia—Cisplatin—testicular cancer	0.00112	0.00254	CcSEcCtD
Methazolamide—Discomfort—Etoposide—testicular cancer	0.00111	0.00252	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.0011	0.00251	CcSEcCtD
Methazolamide—Confusional state—Etoposide—testicular cancer	0.00108	0.00246	CcSEcCtD
Methazolamide—Urticaria—Ifosfamide—testicular cancer	0.00108	0.00246	CcSEcCtD
Methazolamide—Body temperature increased—Ifosfamide—testicular cancer	0.00108	0.00245	CcSEcCtD
Methazolamide—Pancytopenia—Methotrexate—testicular cancer	0.00108	0.00244	CcSEcCtD
Methazolamide—Anaphylactic shock—Etoposide—testicular cancer	0.00108	0.00244	CcSEcCtD
Methazolamide—Asthenia—Dactinomycin—testicular cancer	0.00107	0.00242	CcSEcCtD
Methazolamide—Paraesthesia—Cisplatin—testicular cancer	0.00105	0.0024	CcSEcCtD
Methazolamide—Photosensitivity reaction—Methotrexate—testicular cancer	0.00103	0.00235	CcSEcCtD
Methazolamide—Anorexia—Etoposide—testicular cancer	0.00102	0.00233	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.00102	0.00232	CcSEcCtD
Methazolamide—Decreased appetite—Cisplatin—testicular cancer	0.00102	0.00232	CcSEcCtD
Methazolamide—Diarrhoea—Dactinomycin—testicular cancer	0.00102	0.00231	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00101	0.0023	CcSEcCtD
Methazolamide—Vomiting—Bleomycin—testicular cancer	0.00101	0.0023	CcSEcCtD
Methazolamide—Drowsiness—Methotrexate—testicular cancer	0.00101	0.0023	CcSEcCtD
Methazolamide—Pancytopenia—Epirubicin—testicular cancer	0.00101	0.00229	CcSEcCtD
Methazolamide—Rash—Bleomycin—testicular cancer	0.001	0.00228	CcSEcCtD
Methazolamide—Dermatitis—Bleomycin—testicular cancer	0.001	0.00228	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.001	0.00228	CcSEcCtD
Methazolamide—Asthenia—Ifosfamide—testicular cancer	0.000977	0.00222	CcSEcCtD
Methazolamide—Photosensitivity reaction—Epirubicin—testicular cancer	0.000967	0.0022	CcSEcCtD
Methazolamide—Feeling abnormal—Cisplatin—testicular cancer	0.000967	0.0022	CcSEcCtD
Methazolamide—Paraesthesia—Etoposide—testicular cancer	0.000965	0.00219	CcSEcCtD
Methazolamide—Haematuria—Methotrexate—testicular cancer	0.000963	0.00219	CcSEcCtD
Methazolamide—Somnolence—Etoposide—testicular cancer	0.000956	0.00217	CcSEcCtD
Methazolamide—Nausea—Bleomycin—testicular cancer	0.000946	0.00215	CcSEcCtD
Methazolamide—Drowsiness—Epirubicin—testicular cancer	0.000945	0.00215	CcSEcCtD
Methazolamide—Vomiting—Dactinomycin—testicular cancer	0.000945	0.00215	CcSEcCtD
Methazolamide—Agranulocytosis—Methotrexate—testicular cancer	0.000942	0.00214	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000937	0.00213	CcSEcCtD
Methazolamide—Rash—Dactinomycin—testicular cancer	0.000937	0.00213	CcSEcCtD
Methazolamide—Decreased appetite—Etoposide—testicular cancer	0.000935	0.00212	CcSEcCtD
Methazolamide—Diarrhoea—Ifosfamide—testicular cancer	0.000931	0.00212	CcSEcCtD
Methazolamide—Pancytopenia—Doxorubicin—testicular cancer	0.000931	0.00212	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Etoposide—testicular cancer	0.000928	0.00211	CcSEcCtD
Methazolamide—Body temperature increased—Cisplatin—testicular cancer	0.000928	0.00211	CcSEcCtD
Methazolamide—Fatigue—Etoposide—testicular cancer	0.000927	0.00211	CcSEcCtD
Methazolamide—Haematuria—Epirubicin—testicular cancer	0.000901	0.00205	CcSEcCtD
Methazolamide—Photosensitivity reaction—Doxorubicin—testicular cancer	0.000895	0.00203	CcSEcCtD
Methazolamide—Feeling abnormal—Etoposide—testicular cancer	0.000886	0.00201	CcSEcCtD
Methazolamide—Nausea—Dactinomycin—testicular cancer	0.000882	0.00201	CcSEcCtD
Methazolamide—Agranulocytosis—Epirubicin—testicular cancer	0.000882	0.002	CcSEcCtD
Methazolamide—Drowsiness—Doxorubicin—testicular cancer	0.000874	0.00199	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000867	0.00197	CcSEcCtD
Methazolamide—Vomiting—Ifosfamide—testicular cancer	0.000866	0.00197	CcSEcCtD
Methazolamide—Rash—Ifosfamide—testicular cancer	0.000858	0.00195	CcSEcCtD
Methazolamide—Dermatitis—Ifosfamide—testicular cancer	0.000858	0.00195	CcSEcCtD
Methazolamide—Erythema multiforme—Methotrexate—testicular cancer	0.000857	0.00195	CcSEcCtD
Methazolamide—Urticaria—Etoposide—testicular cancer	0.000854	0.00194	CcSEcCtD
Methazolamide—Body temperature increased—Etoposide—testicular cancer	0.00085	0.00193	CcSEcCtD
Methazolamide—Tinnitus—Methotrexate—testicular cancer	0.000845	0.00192	CcSEcCtD
Methazolamide—Asthenia—Cisplatin—testicular cancer	0.000842	0.00191	CcSEcCtD
Methazolamide—Haematuria—Doxorubicin—testicular cancer	0.000834	0.00189	CcSEcCtD
Methazolamide—Agranulocytosis—Doxorubicin—testicular cancer	0.000816	0.00185	CcSEcCtD
Methazolamide—Nausea—Ifosfamide—testicular cancer	0.000809	0.00184	CcSEcCtD
Methazolamide—Diarrhoea—Cisplatin—testicular cancer	0.000803	0.00183	CcSEcCtD
Methazolamide—Erythema multiforme—Epirubicin—testicular cancer	0.000802	0.00182	CcSEcCtD
Methazolamide—Tinnitus—Epirubicin—testicular cancer	0.000791	0.0018	CcSEcCtD
Methazolamide—Dysgeusia—Methotrexate—testicular cancer	0.000773	0.00176	CcSEcCtD
Methazolamide—Asthenia—Etoposide—testicular cancer	0.000771	0.00175	CcSEcCtD
Methazolamide—Vomiting—Cisplatin—testicular cancer	0.000746	0.0017	CcSEcCtD
Methazolamide—Erythema multiforme—Doxorubicin—testicular cancer	0.000742	0.00169	CcSEcCtD
Methazolamide—Rash—Cisplatin—testicular cancer	0.00074	0.00168	CcSEcCtD
Methazolamide—Dermatitis—Cisplatin—testicular cancer	0.000739	0.00168	CcSEcCtD
Methazolamide—Diarrhoea—Etoposide—testicular cancer	0.000736	0.00167	CcSEcCtD
Methazolamide—Ill-defined disorder—Methotrexate—testicular cancer	0.000732	0.00166	CcSEcCtD
Methazolamide—Tinnitus—Doxorubicin—testicular cancer	0.000732	0.00166	CcSEcCtD
Methazolamide—Dysgeusia—Epirubicin—testicular cancer	0.000723	0.00164	CcSEcCtD
Methazolamide—Malaise—Methotrexate—testicular cancer	0.000712	0.00162	CcSEcCtD
Methazolamide—Vertigo—Methotrexate—testicular cancer	0.000709	0.00161	CcSEcCtD
Methazolamide—Leukopenia—Methotrexate—testicular cancer	0.000706	0.00161	CcSEcCtD
Methazolamide—Nausea—Cisplatin—testicular cancer	0.000697	0.00158	CcSEcCtD
Methazolamide—Ill-defined disorder—Epirubicin—testicular cancer	0.000685	0.00156	CcSEcCtD
Methazolamide—Convulsion—Methotrexate—testicular cancer	0.000684	0.00155	CcSEcCtD
Methazolamide—Vomiting—Etoposide—testicular cancer	0.000684	0.00155	CcSEcCtD
Methazolamide—Rash—Etoposide—testicular cancer	0.000678	0.00154	CcSEcCtD
Methazolamide—Dermatitis—Etoposide—testicular cancer	0.000677	0.00154	CcSEcCtD
Methazolamide—Headache—Etoposide—testicular cancer	0.000674	0.00153	CcSEcCtD
Methazolamide—Dysgeusia—Doxorubicin—testicular cancer	0.000669	0.00152	CcSEcCtD
Methazolamide—Malaise—Epirubicin—testicular cancer	0.000666	0.00151	CcSEcCtD
Methazolamide—Discomfort—Methotrexate—testicular cancer	0.000664	0.00151	CcSEcCtD
Methazolamide—Vertigo—Epirubicin—testicular cancer	0.000663	0.00151	CcSEcCtD
Methazolamide—Leukopenia—Epirubicin—testicular cancer	0.000661	0.0015	CcSEcCtD
Methazolamide—Confusional state—Methotrexate—testicular cancer	0.000649	0.00148	CcSEcCtD
Methazolamide—Anaphylactic shock—Methotrexate—testicular cancer	0.000644	0.00146	CcSEcCtD
Methazolamide—Convulsion—Epirubicin—testicular cancer	0.00064	0.00145	CcSEcCtD
Methazolamide—Nausea—Etoposide—testicular cancer	0.000639	0.00145	CcSEcCtD
Methazolamide—Ill-defined disorder—Doxorubicin—testicular cancer	0.000634	0.00144	CcSEcCtD
Methazolamide—Discomfort—Epirubicin—testicular cancer	0.000621	0.00141	CcSEcCtD
Methazolamide—Malaise—Doxorubicin—testicular cancer	0.000616	0.0014	CcSEcCtD
Methazolamide—Vertigo—Doxorubicin—testicular cancer	0.000614	0.0014	CcSEcCtD
Methazolamide—Anorexia—Methotrexate—testicular cancer	0.000614	0.0014	CcSEcCtD
Methazolamide—Leukopenia—Doxorubicin—testicular cancer	0.000612	0.00139	CcSEcCtD
Methazolamide—Confusional state—Epirubicin—testicular cancer	0.000608	0.00138	CcSEcCtD
Methazolamide—Anaphylactic shock—Epirubicin—testicular cancer	0.000603	0.00137	CcSEcCtD
Methazolamide—Convulsion—Doxorubicin—testicular cancer	0.000592	0.00135	CcSEcCtD
Methazolamide—Paraesthesia—Methotrexate—testicular cancer	0.000578	0.00131	CcSEcCtD
Methazolamide—Discomfort—Doxorubicin—testicular cancer	0.000575	0.00131	CcSEcCtD
Methazolamide—Anorexia—Epirubicin—testicular cancer	0.000575	0.00131	CcSEcCtD
Methazolamide—Somnolence—Methotrexate—testicular cancer	0.000573	0.0013	CcSEcCtD
Methazolamide—Dyspepsia—Methotrexate—testicular cancer	0.000567	0.00129	CcSEcCtD
Methazolamide—Confusional state—Doxorubicin—testicular cancer	0.000562	0.00128	CcSEcCtD
Methazolamide—Decreased appetite—Methotrexate—testicular cancer	0.00056	0.00127	CcSEcCtD
Methazolamide—Anaphylactic shock—Doxorubicin—testicular cancer	0.000558	0.00127	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000556	0.00126	CcSEcCtD
Methazolamide—Fatigue—Methotrexate—testicular cancer	0.000555	0.00126	CcSEcCtD
Methazolamide—Paraesthesia—Epirubicin—testicular cancer	0.000541	0.00123	CcSEcCtD
Methazolamide—Somnolence—Epirubicin—testicular cancer	0.000536	0.00122	CcSEcCtD
Methazolamide—Anorexia—Doxorubicin—testicular cancer	0.000532	0.00121	CcSEcCtD
Methazolamide—Feeling abnormal—Methotrexate—testicular cancer	0.000531	0.00121	CcSEcCtD
Methazolamide—Dyspepsia—Epirubicin—testicular cancer	0.000531	0.00121	CcSEcCtD
Methazolamide—Decreased appetite—Epirubicin—testicular cancer	0.000524	0.00119	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00052	0.00118	CcSEcCtD
Methazolamide—Fatigue—Epirubicin—testicular cancer	0.00052	0.00118	CcSEcCtD
Methazolamide—Urticaria—Methotrexate—testicular cancer	0.000512	0.00116	CcSEcCtD
Methazolamide—Body temperature increased—Methotrexate—testicular cancer	0.000509	0.00116	CcSEcCtD
Methazolamide—Paraesthesia—Doxorubicin—testicular cancer	0.000501	0.00114	CcSEcCtD
Methazolamide—Feeling abnormal—Epirubicin—testicular cancer	0.000497	0.00113	CcSEcCtD
Methazolamide—Somnolence—Doxorubicin—testicular cancer	0.000496	0.00113	CcSEcCtD
Methazolamide—Dyspepsia—Doxorubicin—testicular cancer	0.000491	0.00112	CcSEcCtD
Methazolamide—Decreased appetite—Doxorubicin—testicular cancer	0.000485	0.0011	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000481	0.00109	CcSEcCtD
Methazolamide—Fatigue—Doxorubicin—testicular cancer	0.000481	0.00109	CcSEcCtD
Methazolamide—Urticaria—Epirubicin—testicular cancer	0.000479	0.00109	CcSEcCtD
Methazolamide—Body temperature increased—Epirubicin—testicular cancer	0.000476	0.00108	CcSEcCtD
Methazolamide—Asthenia—Methotrexate—testicular cancer	0.000462	0.00105	CcSEcCtD
Methazolamide—Feeling abnormal—Doxorubicin—testicular cancer	0.00046	0.00104	CcSEcCtD
Methazolamide—Urticaria—Doxorubicin—testicular cancer	0.000443	0.00101	CcSEcCtD
Methazolamide—Body temperature increased—Doxorubicin—testicular cancer	0.000441	0.001	CcSEcCtD
Methazolamide—Diarrhoea—Methotrexate—testicular cancer	0.000441	0.001	CcSEcCtD
Methazolamide—Asthenia—Epirubicin—testicular cancer	0.000432	0.000983	CcSEcCtD
Methazolamide—Diarrhoea—Epirubicin—testicular cancer	0.000412	0.000937	CcSEcCtD
Methazolamide—Vomiting—Methotrexate—testicular cancer	0.000409	0.000931	CcSEcCtD
Methazolamide—Rash—Methotrexate—testicular cancer	0.000406	0.000923	CcSEcCtD
Methazolamide—Dermatitis—Methotrexate—testicular cancer	0.000406	0.000922	CcSEcCtD
Methazolamide—Headache—Methotrexate—testicular cancer	0.000403	0.000917	CcSEcCtD
Methazolamide—Asthenia—Doxorubicin—testicular cancer	0.0004	0.000909	CcSEcCtD
Methazolamide—Vomiting—Epirubicin—testicular cancer	0.000383	0.000871	CcSEcCtD
Methazolamide—Nausea—Methotrexate—testicular cancer	0.000383	0.00087	CcSEcCtD
Methazolamide—Diarrhoea—Doxorubicin—testicular cancer	0.000382	0.000867	CcSEcCtD
Methazolamide—Rash—Epirubicin—testicular cancer	0.00038	0.000864	CcSEcCtD
Methazolamide—Dermatitis—Epirubicin—testicular cancer	0.00038	0.000863	CcSEcCtD
Methazolamide—Headache—Epirubicin—testicular cancer	0.000378	0.000858	CcSEcCtD
Methazolamide—Nausea—Epirubicin—testicular cancer	0.000358	0.000814	CcSEcCtD
Methazolamide—Vomiting—Doxorubicin—testicular cancer	0.000355	0.000806	CcSEcCtD
Methazolamide—Rash—Doxorubicin—testicular cancer	0.000352	0.000799	CcSEcCtD
Methazolamide—Dermatitis—Doxorubicin—testicular cancer	0.000351	0.000798	CcSEcCtD
Methazolamide—Headache—Doxorubicin—testicular cancer	0.000349	0.000794	CcSEcCtD
Methazolamide—Nausea—Doxorubicin—testicular cancer	0.000331	0.000753	CcSEcCtD
